Merck’S Remigromig, A Tri-Specific Agonist Of The Wingless-Related Integration Site Pathway, Met Primary Endpoint In The Pivotal Phase 2B/3 Brunello Study Of Adults With Diabetic Macular Edema
Merck & Co Inc NYSE:MRK
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
7 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
BRIEF — Merck’S Remigromig, A Tri — Specific Agonist Of The Wingless — Related Integration Site Pathway, Met Primary Endpoint In The Pivotal Phase 2B/3 Brunello Study Of Adults With Diabetic Macular Edema
Sept 24 (Reuters) — Merck & Co Inc: Merck’s Remigromig, A Tri-specific Agonist Of The Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint In The Pivotal Phase 2b/3 Brunello Study Of Adults With Diabetic Macular Edema Merck & Co - Remigromig Demonstrates Non-inferiority To Ranibizumab For Bcva At Week
Merck’s Remigromig, A, Met Primary Endpoint In Phase 2b/3 Brunello Study Of Adults With Diabetic Macular Edema
Merck’s Remigromig, A, Met Primary Endpoint In Phase 2b/3 Brunello Study Of Adults With Diabetic Macular Edema
Merck says remigromig meets primary endpoint in pivotal BRUNELLO trial for diabetic macular edema
Merck reported topline results from the pivotal Phase 2b/3 BRUNELLO trial of remigromig in adults with diabetic macular edema. Year-one data will be presented Oct. 10 at the American Academy of Ophthalmology Annual Meeting. Both remigromig doses met the primary goal, matching ranibizumab on vision outcomes over 52 week
Merck’s Remigromig, a Tri — specific Agonist of the Wingless — related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
For best results when printing this announcement, please click on link below: Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema Remigromig demonstrated non-inferiority to
Merck & Co., Inc., Rahway, N.J., USA DME Drug Meets Phase 2b/3 Non-Inferiority
Merck said remigromig met the primary endpoint of non-inferiority to 0.5 mg ranibizumab in BCVA at 52 weeks in the pivotal Phase 2b/3 BRUNELLO DME trial; higher rates of PDR, vitreous hemorrhage, and AE-related discontinuations were seen vs ranibizumab.Material DetailsContext by AI AnalystThis is a…
Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema (DME). BRUNELLO is the first of two Phase 2b/3 trials evaluating the safety and efficacy of remigromig (MK-3000…